MONTREAL–(BUSINESS WIRE)–Giiant Pharma Inc., a preclinical-stage biotech company developing gut-restricted drug therapeutics in gastroenterology, announced the appointment of a seasoned executive as an independent board member.
Dr. Marie Lindner worked in various executive roles in pharmaceutical, biotech, venture capital, start-up and medtech companies, spending over 30 years in multiple therapeutic areas, including gastroenterology.
“I am thrilled to join Giiant’s endeavor in advancing their lead program GT-2018, and to support them with their various development programs. I believe my background and expertise will be an effective complement to the company’s already strong R&D strategy and business development,” said Dr. Lindner.
“We are privileged to have Marie joining our Board of Directors. Her appointment will be pivotal for the company growth,” added Maxime Ranger, CEO of Giiant Pharma.
Following an esteemed academic and medical career, Marie Lindner, is active on several boards. She was most recently focused on finding new trends in science and medicine at Novartis, as Global Program Head, Strategic Partnerships Team.
About Giiant Pharma
Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.